Michael Popadynec

ORCID: 0000-0002-0561-0129
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Marine Toxins and Detection Methods
  • Helicobacter pylori-related gastroenterology studies
  • Marine Sponges and Natural Products
  • Crystallization and Solubility Studies
  • X-ray Diffraction in Crystallography
  • Clostridium difficile and Clostridium perfringens research
  • CRISPR and Genetic Engineering
  • Advanced biosensing and bioanalysis techniques
  • Microbial bioremediation and biosurfactants
  • RNA and protein synthesis mechanisms
  • Chemical Synthesis and Analysis
  • Nicotinic Acetylcholine Receptors Study
  • Click Chemistry and Applications
  • Viral gastroenteritis research and epidemiology
  • Protist diversity and phylogeny
  • Synthetic Organic Chemistry Methods
  • Synthesis and Catalytic Reactions

Victoria University of Wellington
2021-2024

AstraZeneca (United Kingdom)
2020

University of Glasgow
2020

Ceralasertib is currently being evaluated in multiple phase I/II clinical trials for the treatment of cancer. Its structure, comprising a pyrimidine core decorated with chiral morpholine, cyclopropyl sulfoximine and an azaindole, makes it challenging molecule to synthesize on large scale. Several features medicinal chemistry early development route make unsuitable long-term commercial manufacture active pharmaceutical ingredient. We describe investigation new improved which introduces moiety...

10.1021/acs.oprd.0c00482 article EN Organic Process Research & Development 2020-12-15

A novel four-step bidirectional strategy has been used to synthesize the IJK fragment of marine polyether natural product CTX3C from a simple monocyclic precursor in concise and efficient manner. The sequence involves ring-closing metathesis, alcohol oxidation, enol carbonate formation, palladium-mediated Tsuji–Trost allylation.

10.1021/acs.orglett.0c01238 article EN cc-by Organic Letters 2020-04-19

Clostridioides difficile causes life-threatening diarrhea and is one of the leading nosocomial infections. During infection, C. releases two gut-damaging toxins, TcdA TcdB, which are primary determinants disease pathogenesis important therapeutic targets. Once in cytosol mammalian cells, TcdB use UDP-glucose to glucosylate host Rho GTPases, leads cytoskeletal changes that result a loss intestinal integrity. Isofagomine inhibits as mimic glucocation transition state glucosyltransferase...

10.1021/acsinfecdis.3c00507 article EN ACS Infectious Diseases 2024-02-09

A significant proportion of genetic disease cases arise from truncation proteins caused by premature termination codons. In eukaryotic cells some aminoglycosides cause readthrough codons during protein translation. Inducing these can potentially be therapeutic value in the treatment numerous diseases. drawback to repeated use as treatments is lack balance between their efficacy and toxicity. The synthesis biological testing designer aminoglycoside compounds documented herein. We disclose...

10.1021/acsmedchemlett.1c00349 article EN ACS Medicinal Chemistry Letters 2021-08-09

The I-L ring system found in all the Pacific ciguatoxins has been prepared from a tricyclic precursor highly stereoselective manner. Subtle differences reactivity of enones present seven- and eight-membered rings ether starting material have exploited to allow selective protection enone ring. Subsequent distereoselective allylation seven-membered accomplished by palladium-mediated Tsuji-Trost reaction. K-ring methyl hydroxyl groups installed manner sequential conjugate reduction enolate...

10.3390/toxins12120740 article EN cc-by Toxins 2020-11-24

Abstract Clostridioides difficile causes life-threatening diarrhea and is the leading cause of healthcare associated bacterial infections in United States. During infection, C. releases gut-damaging toxins, TcdA TcdB, primary determinants disease pathogenesis are therefore therapeutic targets. TcdB contain a glycosyltransferase domain that uses UDP-glucose to glycosylate host Rho GTPases, causing cytoskeletal changes result loss intestinal integrity. Isofagomine inhibits as mimic...

10.1101/2023.09.19.558375 preprint EN cc-by-nc-nd bioRxiv (Cold Spring Harbor Laboratory) 2023-09-19
Coming Soon ...